The unbiased method minimizes tearing of cells and inserts circulating tumor cells and leukocytes into a custom cell culture medium for later downstream analysis.
The funding will help the San Francisco-based firm apply low-depth NGS as it builds diagnostic tests to aid therapy selection in more diverse populations.
The deals give 10x Genomics control of a combined 110 patents covering in situ analysis methods that the firm says will complement its existing platforms.
The firm's Nanotrap virus particles provide an alternative to RNA extraction kits and could help improve detection for respiratory viruses, including SARS-CoV-2.
The submission data highlights Parsortix's ability to harvest circulating tumor cells from metastatic breast cancer patient blood samples for downstream analysis.
The agency is providing the material freely and asking for feedback, so it can fix possible problems before more widely disseminating it to labs and companies.
